Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017684 | 0.88 | MEN1 (0.42) | ALDH1A1CHRM1MEN1KMT2A | |
| SCHEMBL13665501 | 0.86 | DPP4 (0.49) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL1712955 | 0.86 | DPP4 (0.49) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL1713070 | 0.81 | ALDH1A1 (0.42) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL5564424 | 0.79 | ALDH1A1 (0.67) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL2606048 | 0.79 | ALDH1A1 (0.67) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL4164572 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL21159869 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NPC1DPP4CHRM2CHRM4 | |
| SCHEMBL15615966 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NPC1AKR1C3NAMPTMEN1 | |
| SCHEMBL19973506 | 0.79 | ALDH1A1 (0.41) | ALDH1A1NPC1AKR1C3NAMPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2020-10-01 | — | — | US | disclosed |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2019-06-13 | — | — | US | disclosed |
| WO-2017106556-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2345629-B1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2015-06-03 | — | — | EP | disclosed |
| US-8871934-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2014-10-28 | — | — | US | disclosed |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-8343994-B2 | Fluorene compound and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2013-01-01 | — | — | US | disclosed |
| EP-2345629-A1 | FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-6770666-B2 | A THERAPEUTIC AGENT FOR TREATING HEPATITIS C, BASED ON POLYMERASE INHIBITORY ACTIVITY | JAPAN TOBACCO INC. (JP) | 2004-08-03 | — | — | US | disclosed |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2004-05-20 | — | — | US | disclosed |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1400241-A1 | FUSED CYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003103652-A1 | METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | JAPAN TOBACCO INC. (JP) | 2003-03-13 | — | — | US | disclosed |
| EP-1162196-A1 | FUSED-RING COMPOUNDS AND USE THEREOF AS DRUGS | JAPAN TOBACCO INC. (JP) | 2001-12-12 | — | — | EP | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329491-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | ALDH1A1 1793/4885NPC1 461/4885DPP4 968/4885 |
| US-20040082635-A1 | Viricide against hepatitis virus; polymerase inhibitor | HAVCR2, ZC3HAV1, POLR1C | ALDH1A1 1133/4885NPC1 461/4885DPP4 177/4885 |
| US-20030050320-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, HLA-C | ALDH1A1 463/4885NPC1 100/4885DPP4 91/4885 |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ALDH1A1 1039/4885NPC1 2706/4885DPP4 36/4885 |
| US-20130274240-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | ALDH1A1 1793/4885NPC1 461/4885DPP4 968/4885 |
| US-20190177271-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | ALDH1A1 1793/4885NPC1 461/4885DPP4 968/4885 |
| US-20040097438-A1 | Fused-ring compounds and use thereof as drugs | HAVCR2, ZC3HAV1, SLC10A1 | ALDH1A1 144/4885NPC1 196/4885DPP4 140/4885 |
| US-20200308109-A1 | FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF | FH, PCK2, PC | ALDH1A1 1793/4885NPC1 461/4885DPP4 968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.